Proprietary, state-of-the-art bioinformatic pipelines
allow us to deliver in a timely fashion easy-to-understand results to our customers.
Testo AncoraTesto Ancora
Thanks to the extensive experience of our team and to our set of proprietary IT tools, entirely developed internally and fully customizable, we provide biological data, not just Fastq files.
Galseq developed 2 different software to analyze microbiome data with Dynamic Krona-like analysis, Alpha and beta diversity, Phylogeny/principal correlation.
Microbiome Viewer: for the researcher. Includes several statistics tools and the possibility to customize your analyses and plots.
Microbiome Analyzer: for the nutritionist. With a “run expert system” that suggests behavior with a score to improve patients' diet habits.Testo Ancora
Single-cell RNA analysis
Single-cell RNA sequencing (scRNA-seq) has enabled the expression profiles of individual cells to be studied at an unprecedented resolution. A lot of different analysis tools are becoming available and we offer an up-to-date workflow to analyse your data. We including pre‐processing (quality control, normalization, data correction, feature selection, and dimensionality reduction) and cell‐ and gene‐level downstream analysis.Testo AncoraREQUEST INFO
Fusion Analyser is an efficient and robust graphical tool developed by our team for the identification of functional rearrangements through the analysis of paired-end transcriptome sequencing data. The availability of user-friendly fusion-detection tools, being able to identify new and known fusions at nucleotide resolution even in the absence of mitotic events and when the availability of cancer cells is limited, can have a profound impact in basic as well as clinical research.Testo AncoraREQUEST INFO
CEQer (Comparative Exome Quantification analyzer) is a graphical, event-driven tool developed by our team for CNA/allelic-imbalance (AI) coupled analysis of exome sequencing data. By using case-control matched exome data, CEQer performs a comparative digital exonic quantification to generate CNA data and couples this information with exome-wide LOH and allelic imbalance detection. This data is used to build mixed statistical/heuristic models allowing the identification of CNA/AI events.Testo AncoraREQUEST INFO
OncoScore is an Internet-based tool to assess the oncogenic potential of genes. TRY IT
It’s a text-mining tool that ranks genes according to their association with cancer, based on available biomedical literature. Receiver operating characteristic curve and the area under the curve (AUC) metrics on manually curated datasets confirmed the excellent discriminating capability of OncoScore (OncoScore cut-off threshold = 21.09; AUC = 90.3%, 95% CI: 88.1–92.5%), indicating that OncoScore provides useful results in cases where an efficient prioritization of cancer-associated genes is needed.
Scientific Reports (2017)Testo Ancora
Splice Finder software
SpliceFinder is a bioinformatic tool developed by our team for detection, from case-control matched exome data, of somatic variants occurring at the exon-intron boundary potentially causing splicing abnormalities. SpliceFinder approach is based on two main steps. In the first step we annotate the variations detected by whole‐exome sequencing and we predict from the non-exonic variants those with a damaging effect on RNA splicing in cancer samples and in the second step we confirm the splicing variants prediction by using two canonical splice‐site analysis tools developed for single mutation analysis.REQUEST INFO
SAM-Profiler includes several quality reporting algorithms, namely: mean and per-chromosome Read quality, Mapping quality, Paired-end Read Quality, Duplicate Analysis, Exonic, Intronic, Intergenic Coverage, mean Exonic fold-coverage, Fragment Size Distribution, Mapping Profile, Single or Paired-Read Mismatch Distribution, CG Distribution and Nucleotides Distribution. The output file is then processed to generate the graphical report. Two different internal pipelines are implemented, depending on whether a SAM or a BAM file is under processing.REQUEST INFO